ArticleArquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery2026
Association of Helicobacter pylori and Epstein-Barr virus co-infection in gastric cancer patients: a prospective analytical study.
Article in Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecent evidence suggests that Epstein-Barr virus (EBV) and Helicobacter pylori co-infection increase the prevalence of gastric cancer in the younger age group and are associated with poor prognosis. Identifying the association between these agents has important implications for the management of gastric cancer and also for defining populations at high risk of developing gastric malignancy.
aimsTo determine the prevalence of H. pylori and EBV co-infection in patients with gastric cancer.
methodsThis is a single-center prospective analytical study. A total of 182 patients were included. The study group (n=91) comprised all consecutive patients of age ≥18 years with gastric cancer. The control group (n=91) included individuals with normal endoscopy findings. Both groups were analyzed for the presence of H. pylori and EBV.
resultsThe overall prevalence of H. pylori infection in gastric cancer patients was 70.3%, EBV infection was 63.7%, and H. pylori and EBV co-infection was 51.6%. The H. pylori and EBV co-infection in the study and control groups was 51.6% versus 13.1% (p<0.001). The remaining parameters such as smoking, socioeconomic class, dietary habits, prior gastric surgery, tumor location, histological subtype, stage of the tumor, distant metastasis, and lymph node metastasis did not show any significance.
conclusionsThere was a significantly higher prevalence of EBV infection and H. pylori and EBV co-infection in patients with gastric cancer. The prognostic and therapeutic role of co-infection requires long-term follow-up and assessment of treatment response. CENTRAL MESSAGE: The strongest known environmental risk factor for developing gastric cancer is prolonged colonization with Helicobacter pylori. More than 50% of the world's population harbors H. pylori in the gastric mucosa. Epstein-Barr virus (EBV), which is associated with many hematological malignancies, is now considered to be associated with the development of gastric cancer. Studies have reported that 9% of gastric cancer cases are associated with EBV infection. The association of EBV and H. pylori co-infection in gastric cancer has not been extensively investigated. PERSPECTIVES: Epstein-Barr virus (EBV) infection appears to be more prevalent in gastric cancer compared to the normal population. Also, most of the gastric cancer patients have co-infection of both Helicobacter pylori and EBV. The importance of this observation indicates that H. pylori eradication alone does not help in the prevention of gastric cancer. EBV infection, which augments the damage caused by H. pylori, requires a specific targeted therapy. In the future, individuals with a high risk of gastric cancer may benefit from the targeted drug against the EBV-lytic cycle protein, with the aim of preventing reactivation of the virus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.